Prophylactic anticoagulation tied to lower death rate in COVID
June 18, 2021
Prophylactic use of low-dose anticoagulation to prevent venous thromboembolism was associated with reduced 60-day mortality in patients hospitalized with COVID-19 in Michigan.
Factor XI inhibitor–based anticoagulation strategies gain ground
November 18, 2020
“When we compare the FXI inhibitors with existing anticoagulants, we don’t necessarily want to go up against the DOACs.”
HOME-PE trial clarifies which pulmonary embolism patients to treat at home
September 1, 2020
“Who’s happy with the HOME-PE trial? I think everybody.” – Dr. Stavros V. Konstantinides
PCSK9 inhibitors unexpectedly link with lower VTE, aortic stenosis
April 21, 2020
Post hoc analyses of data from as many as 46,000 patients showed surprising links between PCSK9 inhibition and reduced rates of VTE and aortic stenosis.
New ASH guideline: VTE prophylaxis after major surgery
December 12, 2019
ORLANDO – The chair of VTE guidelines panel presented highlights of the latest guidelines in a special session at the annual meeting of the American Society of Hematology.
Smokers with PE have higher rate of hospital readmission
November 11, 2019
NEW ORLEANS – The rate of readmission within 30 days was significantly higher among PE patients with tobacco dependence.
FDA approves rivaroxaban for VTE prevention in hospitalized, acutely ill patients
October 15, 2019
The latest approval is based on results from the phase 3 MAGELLAN and MARINER trials, which included more than 20,000 patients.
Older IBD patients are most at risk of postdischarge VTE
September 10, 2019
Readmission for venous thromboembolism in patients with inflammatory bowel diseases most often occurs within 60 days of discharge.
No reduction in PE risk with vena cava filters after severe injury
July 9, 2019
MELBOURNE – “Given the cost and risks associated with a vena cava filter, our data suggest that there is no urgency to insert the filter in patients who can be treated with prophylactic anticoagulation within 7 days after injury,” the investigators wrote.
Rivaroxaban tied to higher GI bleeding than other NOACs
June 17, 2019
SAN DIEGO – Real-world studies comparing the GI bleeding rates among different non–vitamin K anticoagulants have been limited.